Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ubix Therapeutics SHP2 compound 5
- Development stage
- Unknown
- Lead developer
- Ubix Therapeutics
01
Overview
Ubix Therapeutics SHP2 compound 5: sourced facts only. name: "Phosphatase panel profiling and proteomics demonstrated compound 5 degraded SHP2 selectively." [DOI:10.1158/1538-7445.am2025-1661]; target: "Phosphatase panel profiling and proteomics demonstrated compound 5 degraded SHP2 selectively." [DOI:10.1158/1538-7445.am2025-1661]; developer: "Ubix Therapeutics Co., Ltd., Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2025-1661]
02
Targets
PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on Ubix Therapeutics SHP2 compound 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ubix Therapeutics SHP2 compound 5.